Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO, shared a post on X:
“Are we nearing a paradigm shift in early ER+/HER2- breast cancer?
ESMOBreast25 data from ADAPTcycle & OPTIMA suggest similar outcomes with Ribociclib or MPA-guided ET vs chemo in select patients.
Clinical and genomic risk stratification is key.”
More posts featuring Elvina Almuradova.